2,734.00p+34.00 (+1.26%)02 May 2025, 08:33
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Bioventix PLC Fundamentals

Company NameBioventix PLCLast Updated2025-05-02
IndustryBiotechnologySectorHealthcare
Shares in Issue5.225 mMarket Cap£142.85 m
PE Ratio17.22Dividend per Share£1.58
Dividend Yield6.16Dividend Cover0.97
EPS£1.53EPS Growth (%)-0.02
PEG0DPS Growth (%)0.1618
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.1535Cash Equity Ratio0.4559
Quick Ratio6.6923Current Ratio7.01
Price To Book Value12.5000ROCE0

Bioventix PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total
Interim2025-04-102025-04-25GBP0.7000
Prelim2024-11-072024-11-21GBP0.8700
Interim2024-04-112024-04-26GBP0.6800
Prelim2023-11-092023-11-24GBP0.9000
Interim2023-04-062023-04-21GBP0.6200
Prelim2022-11-032022-11-18GBP0.7400

Bioventix PLC Company Financials

Assets202420232022
Tangible Assets£477,997.00£575,726.00£694,370.00
Intangible Assets000
Investments£426,733.00£610,039.00£610,039.00
Total Fixed Assets£904,730.00£1.19 m£1.30 m
Stocks£615,345.00£565,366.00£461,815.00
Debtors£6.21 m£5.81 m£5.22 m
Cash & Equivalents£6.00 m£5.72 m£6.13 m
Other Assets000
Total Assets£13.73 m£13.28 m£13.12 m
Liabilities202420232022
Creditors within 1 year£1.73 m£1.20 m£1.25 m
Creditors after 1 year0£18,224.00£44,276.00
Other Liabilities000
Total Liabilities£1.73 m£1.22 m£1.30 m
Net assets£12.00 m£12.06 m£11.82 m
Equity202420232022
Called up share capital£260,983.00£260,983.00£260,467.00
Share Premium£1.47 m£1.47 m£1.33 m
Profit / Loss£10.60 m£10.13 m£9.28 m
Other Equity£12.00 m£12.06 m£11.82 m
Preference & Minorities000
Total Capital Employed£12.00 m£12.06 m£11.82 m
Ratios202420232022
Debt Ratio000
Debt-to-Equity000
Assets / Equity1.15351.15351.1535
Cash / Equity0.45590.45590.4559
EPS£1.58£1.61£1.47
Cash Flow202420232022
Cash from operating activities£8.34 m£7.80 m£7.56 m
Cashflow before financing£97,079.00-£501,342.00-£361,383.00
Increase in Cash£283,134.00-£410,831.00-£368,335.00
Income202420232022
Turnover£13.61 m£12.82 m£11.72 m
Cost of sales£925,527.00£828,410.00£710,446.00
Gross Profit£12.68 m£11.99 m£11.01 m
Operating Profit£10.58 m£10.03 m£9.27 m
Pre-Tax profit£10.60 m£10.13 m£9.28 m

Bioventix PLC Company Background

SectorHealthcare
ActivitiesBioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
Latest Interim Date31 Mar 2025
Latest Fiscal Year End Date28 Oct 2024

Bioventix PLC Directors

AppointedNamePosition
2025-04-28Mr. Bruce Edward Heath Hiscock Executive Director,Chief Financial Officer
2024-11-11Mr. Ian James NicholsonNon-Executive Director,Chairman
2025-04-16Mr. Peter John HarrisonExecutive Director,Chief Executive Officer
2020-07-01Ms. Treena Joan TurnerNon-Executive Director,Finance Director
2024-11-11Mr. Nicholas John McCookeNon-Executive Director

Bioventix PLC Contact Details

Company NameBioventix PLC
Address27-28 Eastcastle Street, London, W1W 8DH
Telephone+44 1252728001
Websitehttps://www.bioventix.com

Bioventix PLC Advisors

SolicitorCharles Russell Speechlys LLP
Phone+44 2072035000
Nominated AdviserFinnCap
Phone+44 2072200500
Fax+44 2072200597
AuditorJames Cowper Kreston
Phone+44 1189590261
StockbrokerFinnCap
Phone+44 2072200500
Fax+44 2072200597
RegistrarShare Registrars Limited
Phone+44 1252821390
Fax+44 1252719232